Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners, launches its new name “Pharmanovia” to support its strategic vision globally.
Founded in 2013, the company has grown from a small family business operating solely in the UK to a global specialty pharma business, marketing 20+ brands in 140+ markets with over 200 employees. The company earnings have grown 50% year-on-year, for the last 7 years.
Pharmanovia is the former name of Atnahs’ affiliate in the Nordics and a spec pharma business that Atnahs acquired in 2016. Together with the new logo, it expresses the connotation of an innovative pharmaceutical business in progress.
The new brand name and identity reflect Pharmanovia’s position as the original medicines specialist globally, as a committed, progressive global specialty pharma business and preferred partner for innovator pharma companies.
Dr Amit Patel, Chief Executive Officer, explains, “We are delighted to launch the new brand name ‘Pharmanovia‘ for our company today. We are extremely proud of our portfolio of iconic, tried and trusted medicines, that are the proven original treatment option for patients in many countries around the world.
Over the coming years, we plan to progress and evolve this portfolio through the development and co-development of niche, value-add products, the licensing of patent-protected and orphan drugs, and the ongoing acquisition of established and off-patent brands. Our mission remains to be an agile and dynamic global specialty pharma business and a preferred partner to innovator pharma companies. Pharmanovia is the brand name that reflects this mission better.”
Pharmanovia reflects the company’s purpose: The original medicines specialist globally that progresses iconic medicines for the global benefit of patient health.
A new name – “Pharmanovia” was the name of an innovative specialty pharma business, based in Copenhagen and operating throughout the Nordics, that we acquired in 2016. It brings connotations of progress and innovation, while retaining authenticity.
A new logo – the logo represents impulse and movement, reflecting transformation and progression. It neatly captures the strategy of acquiring original, iconic medicines and breathing new life into them through marketing and promotion as well as line extensions (new strengths, new formulations, new markets).
A fresh colour palette – blue plays an important role, creating a strong appearance that represents a dynamic and confident brand but retains its friendliness. In colour theory, blue is the colour of the ocean and the sky; it symbolises serenity, stability, inspiration, wisdom and health.
Enhanced imagery – the imagery tells two stories: one of patients taking part in life again; the other of the agility and commitment of colleagues.
The new brand identity is rolling out across all Pharmanovia’s touchpoints and platforms – internal and external, physical, and digital – from today.
About Pharmanovia – The original medicines specialist globally
Our purpose is to progress iconic medicines for the benefit of patient health globally.
We provide iconic, tried and trusted medicines in the strategic therapeutic areas of Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.
We own some of the world’s most recognisable brands, including Bonviva®, Kytril®, Inderal®, Naprosyn®, Valium®, Zestril® and more.
We operate a portfolio of 20+ brands in 140+ markets with over 200 employees, and we grow through development, licensing and acquisition.
For further information: pharmanovia.com
Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857